Matrix Metalloproteinase 9 - Metabolism
Research News and Information

Monday, November 23, 2009

Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB.

13 Nov 2009 Death receptors of the tumor necrosis factor (TNF) receptor super family have been implicated in constitutive activation of nuclear factor-kappa B (NF-kappaB) in pancreatic cancer (PaC) cells. In this study, we demonstrate that fisetin, a natural ... Read more...

Involvement of cytosolic phospholipase A2alpha in MMP-9 up-regulation.

30 Oct 2009 Matrix metalloproteinase-9 (MMP-9) is important in the pathogenesis of periodontitis. Cytosolic phospholipase A(2)alpha (cPLA(2)alpha) is involved in MMP-9 up-regulation in human monocytes. We tested the hypothesis that cPLA(2)alpha also regulates ... Read more...

Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells.

30 Oct 2009 Matrix metalloproteinase-9 (MMP-9) is a well-known regulator and effecter of many cellular processes including wound healing. In the cornea, either too much or too little MMP-9 can be detrimental to overall wound repair. We investigated the secreted ... Read more...

Latest indexed articles for 'Matrix Metalloproteinase 9 - Metabolism'

These are the very latest articles for this heading:

• Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. 13 Nov 2009
• Involvement of cytosolic phospholipase A2alpha in MMP-9 up-regulation. 30 Oct 2009
• Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. 30 Oct 2009
• CXCL14 inhibits trophoblast outgrowth via a paracrine/autocrine manner during early pregnancy in mice. 30 Oct 2009
• Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9. 3 Oct 2009
• Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. 29 Sep 2009
• Caveolin-1 tumor-promoting role in human melanoma. 29 Sep 2009
• DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin. 29 Sep 2009
• Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. 29 Sep 2009
• Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. 29 Sep 2009
• Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. 29 Sep 2009
• Mesangial cell-derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy. 7 Sep 2009
• Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. 30 Aug 2009
• Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. 30 Aug 2009
• In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. 30 Aug 2009
• Peritumoral administration of GPI-anchored TIMP-1 inhibits colon carcinoma growth in Rag-2 gamma chain-deficient mice. 30 Aug 2009
• MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway. 30 Aug 2009
• Role of Wnt-5A in interleukin-1beta-induced matrix metalloproteinase expression in rabbit temporomandibular joint condylar chondrocytes. 30 Aug 2009
• Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. 30 Aug 2009
• Role of angiotensin II type 1 receptor in cerebral aneurysm formation in rats. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Matrix Metalloproteinase 9'

Definition: An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V.

Registry Number: EC 3.4.24.35

Descriptor UI: D020780

Alternative terms: Matrix Metalloproteinase 9; Metalloproteinase 9, Matrix; 92-kDa Type IV Collagenase; 92 kDa Type IV Collagenase; MMP9 Metalloproteinase; Metalloproteinase, MMP9; Matrix Metalloproteinase-9; MMP-9 Metalloproteinase; MMP 9 Metalloproteinase; Metalloproteinase, MMP-9; 92-kDa Gelatinase; 92 kDa Gelatinase; Gelatinase B;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.277.656.300.480.205.360; D08.811.277.656.300.480.252.445; D08.811.277.656.300.480.525.700.350; D08.811.277.656.675.374.205.360; D08.811.277.656.675.374.252.445; D08.811.277.656.675.374.525.700.350;

History Note: 2007(2000)